Theragnostics Limited (Theragnostics) is pleased to announce the completion of an Exclusive Product Supply and Distribution Agreement with PCCA Ltd for distribution of Theragnostics proprietary prostate cancer imaging THP-PSMA kits in the United Kingdom. Under the agreement, PCCA will distribute THP-PSMA kits for use in compassionate use or “specials” clinical studies in the United Kingdom.
THP-PSMA is currently in clinical development with Theragnostics sponsored Phase II clinical trials ongoing. The THP-PSMA kit enables rapid one-step formation of 68Ga-THP-PSMA which is applied to positron emission tomography (PET) diagnostic imaging in prostate cancer patients.
PCCA Ltd (formerly known as The Specials Laboratory) based in Northumberland, UK are an award-winning company delivering unlicensed medicines (Specials) and Investigational Medicinal Products (IMPs) to thousands of community and hospital pharmacists and doctors throughout the UK and Ireland – usually within 24 hours of an order being placed. For further information visit www.specialslab.co.uk